Cargando…

Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel family of glucose-lowering agents. Accumulating evidence suggests that DPP-4 inhibitors preserve pancreatic beta-cell function, but results in previous studies have been inconsistent. We assessed the effects of DPP-4 inhibitors on the homoeostasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Xiafei, Zhu, Xiaolin, Zhao, Bin, Du, Liang, Chen, Dawei, Wang, Chun, Liu, Guanjian, Ran, Xingwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359588/
https://www.ncbi.nlm.nih.gov/pubmed/28322294
http://dx.doi.org/10.1038/srep44865
_version_ 1782516405988491264
author Lyu, Xiafei
Zhu, Xiaolin
Zhao, Bin
Du, Liang
Chen, Dawei
Wang, Chun
Liu, Guanjian
Ran, Xingwu
author_facet Lyu, Xiafei
Zhu, Xiaolin
Zhao, Bin
Du, Liang
Chen, Dawei
Wang, Chun
Liu, Guanjian
Ran, Xingwu
author_sort Lyu, Xiafei
collection PubMed
description Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel family of glucose-lowering agents. Accumulating evidence suggests that DPP-4 inhibitors preserve pancreatic beta-cell function, but results in previous studies have been inconsistent. We assessed the effects of DPP-4 inhibitors on the homoeostasis model assessment beta-cell function (HOMA-B) or insulin resistance (HOMA-IR) index in patients with type 2 diabetes through a systematic review and meta-analysis of randomized controlled trials (RCTs). Relevant articles were identified from PubMed, Embase, and Cochrane Library databases up to December 27, 2016. We calculated weighted mean differences (WMDs) and 95% confidence intervals (CIs) in each included trial and pooled the data using a random-effects model. Fifty-two trials were included in the present analysis. Compared with placebo control, DPP-4 inhibitors as monotherapy significantly improved HOMA-B (WMD 9.15; 95% CI 7.48, 10.81). Similarly, DPP-4 inhibitors as add-on therapy in combination with other drugs showed significant improvement in HOMA-B (WMD 9.04; 95% CI 5.72, 12.37). However, we found no significant improvement in HOMA-IR following treatment with DPP-4 inhibitors as mono-therapy or as add-on therapy. In conclusion, DPP-4 inhibitors as monotherapy or as add-on therapy significantly improved beta-cell function but had no significant effect on insulin resistance in type 2 diabetes.
format Online
Article
Text
id pubmed-5359588
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53595882017-03-22 Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials Lyu, Xiafei Zhu, Xiaolin Zhao, Bin Du, Liang Chen, Dawei Wang, Chun Liu, Guanjian Ran, Xingwu Sci Rep Article Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel family of glucose-lowering agents. Accumulating evidence suggests that DPP-4 inhibitors preserve pancreatic beta-cell function, but results in previous studies have been inconsistent. We assessed the effects of DPP-4 inhibitors on the homoeostasis model assessment beta-cell function (HOMA-B) or insulin resistance (HOMA-IR) index in patients with type 2 diabetes through a systematic review and meta-analysis of randomized controlled trials (RCTs). Relevant articles were identified from PubMed, Embase, and Cochrane Library databases up to December 27, 2016. We calculated weighted mean differences (WMDs) and 95% confidence intervals (CIs) in each included trial and pooled the data using a random-effects model. Fifty-two trials were included in the present analysis. Compared with placebo control, DPP-4 inhibitors as monotherapy significantly improved HOMA-B (WMD 9.15; 95% CI 7.48, 10.81). Similarly, DPP-4 inhibitors as add-on therapy in combination with other drugs showed significant improvement in HOMA-B (WMD 9.04; 95% CI 5.72, 12.37). However, we found no significant improvement in HOMA-IR following treatment with DPP-4 inhibitors as mono-therapy or as add-on therapy. In conclusion, DPP-4 inhibitors as monotherapy or as add-on therapy significantly improved beta-cell function but had no significant effect on insulin resistance in type 2 diabetes. Nature Publishing Group 2017-03-21 /pmc/articles/PMC5359588/ /pubmed/28322294 http://dx.doi.org/10.1038/srep44865 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Lyu, Xiafei
Zhu, Xiaolin
Zhao, Bin
Du, Liang
Chen, Dawei
Wang, Chun
Liu, Guanjian
Ran, Xingwu
Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
title Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
title_full Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
title_fullStr Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
title_full_unstemmed Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
title_short Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
title_sort effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359588/
https://www.ncbi.nlm.nih.gov/pubmed/28322294
http://dx.doi.org/10.1038/srep44865
work_keys_str_mv AT lyuxiafei effectsofdipeptidylpeptidase4inhibitorsonbetacellfunctionandinsulinresistanceintype2diabetesmetaanalysisofrandomizedcontrolledtrials
AT zhuxiaolin effectsofdipeptidylpeptidase4inhibitorsonbetacellfunctionandinsulinresistanceintype2diabetesmetaanalysisofrandomizedcontrolledtrials
AT zhaobin effectsofdipeptidylpeptidase4inhibitorsonbetacellfunctionandinsulinresistanceintype2diabetesmetaanalysisofrandomizedcontrolledtrials
AT duliang effectsofdipeptidylpeptidase4inhibitorsonbetacellfunctionandinsulinresistanceintype2diabetesmetaanalysisofrandomizedcontrolledtrials
AT chendawei effectsofdipeptidylpeptidase4inhibitorsonbetacellfunctionandinsulinresistanceintype2diabetesmetaanalysisofrandomizedcontrolledtrials
AT wangchun effectsofdipeptidylpeptidase4inhibitorsonbetacellfunctionandinsulinresistanceintype2diabetesmetaanalysisofrandomizedcontrolledtrials
AT liuguanjian effectsofdipeptidylpeptidase4inhibitorsonbetacellfunctionandinsulinresistanceintype2diabetesmetaanalysisofrandomizedcontrolledtrials
AT ranxingwu effectsofdipeptidylpeptidase4inhibitorsonbetacellfunctionandinsulinresistanceintype2diabetesmetaanalysisofrandomizedcontrolledtrials